Category Archives: Pharmacogenomics

Feb. 19, 2020 13:00 UTC

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology images and omics data used together to more precisely identify mechanisms of therapy resistance.

NantOmics scientists trained a deep-neural network on diagnostic slide images from 443 breast tumors that had previously undergone PAM50 subtyping to classify patches of the tumor images into four major molecular subtypes of breast cancer (basal-like, HER2-enriched, luminal A, and luminal B). The algorithm was then validated and demonstrated the capability to establish accurate breast cancer sub-typing in 222 samples from a retained set of tumors. By focusing the neural-networks attention on cancer-rich regions in the diagnostic images, this deep-learning algorithm identifies patient biopsies that are a mixture of different molecular subtypes, a classification that is less definable from molecular pathology techniques. Patients with heterogeneous biopsies such as mixtures of basal-like and luminal disease have a different survival profile than patients with homogeneous disease, and may potentially benefit from a more tailored therapy regimen.

Breast cancer can be subtyped into at least five distinct disease-types with very different prognoses and responses to therapy. These subtypes are characterized as clinically important, yet are typically only achievable by RNA expression profiling, Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth explained. With this AI technique we achieved 87 percent accuracy rate in detecting which patients had basal-like breast cancer (i.e., triple negative breast cancer), one of the most aggressive subtypes, he said.

Our analysis builds on our breadth of advanced machine learning technologies to better support providers in therapeutic decision-making and to improve the capabilities of the underlying molecular analysis technology platforms that we use at NantHealth and NantOmics, said Soon-Shiong. Through the advances of machine vision and augmented intelligence, we have developed a rapid and cost-effective deep-learning technique to unlock the rich information in readily-available diagnostic slide images to define subtypes concordant with their underlying molecular designations.

Breast Cancer Research, a Springer Nature journal, is an international, peer-reviewed online journal publishing original research, reviews, editorials and reports in breast cancer. Breast Cancer Research is published by BMC, an open access publisher that produces over 250 scientific journals and according to its website, is the highest ranked breast cancer focused title in the field.

About NantOmics NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic and machine learning AI capabilities to provide actionable intelligence and molecularly driven decision support for patients and their providers. NantOmics is the first molecular in vitro diagnostics company to accurately identify mutations and true tumor mutation burden (TMB) from proprietary tumor-normal sequencing. The identified mutations and correlative calculation of true TMB, combined with proprietary expression analysis of immuno-oncology biomarkers and novel deep-learning derived digital pathology solutions, establish the framework for the appropriate use of targeted, chemo- and immunotherapies. NantOmics computational analysis engine, an organically grown, scalable, cloud-based infrastructure capable of processing and storing thousands of genomes per day, uses novel AI tools to combine expression analysis with near real-time genomic variance computing to generate precise N of 1 neoepitope vaccine therapies for cancer patients. For more information please visit http://www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantHealth NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Forward-Looking Statements: NantHealth This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005341/en/

Link:
NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of...

Are you genetically predisposed to some diseases? Do you carry genetic mutations that can impact the health of your child? A debit card-sized IndiGenome card, recently unveiled by the government, will help you find the answers if your genetic information is captured in a database that India's umbrella research organisation - the Council of Scientific and Industrial Research (CSIR) - is building. Once your genome is sequenced from your blood sample and added to this database, the card can be used to read the information embedded in your genes, just as your debit card is used to generate a financial transaction statement from your bank's database.

Well, the card is not the key. Genome sequencing - or mapping the pattern of the basic building block of every living cell - is. A genome contains all of a living being's genetic material (simply put, the genome is divided into chromosomes, chromosomes contain genes, and genes are made of DNA). Each genome has approximately 3.2 billion DNA base pairs, and the way they are arranged, or variations and mutations in their pattern, can provide clues about the individual's health or ill health, inherited or acquired. Already, 1,008 individuals, chosen to represent India's social, ethnic and geographic diversity, have been issued such cards. Over 280 doctors in 70 institutions have been trained to make sense of such data. A CSIR institute, the Institute of Genomics and Integrative Biology (IGIB) - which is spearheading the Genomics for Public Health in India, also called IndiGen project - is planning to enrol 20,000 Indians for whole genome sequencing in the next couple of years to build a larger database. The data will be important for building the knowhow, baseline data and indigenous capacity in the emerging

area of precision medicine. IndiGen will have applications in a number of areas, including faster and more efficient diagnosis of rare diseases. The other benefits are cost-effective genetic tests, carrier screening applications for expectant couples, enabling efficient diagnosis of heritable cancers and pharmacogenetic tests to prevent adverse drug reactions.

In fact, IGIB leads two other programmes - Genomics for Understanding Rare Diseases India Alliance (GUaRDIAN) Network and Genomics and other Omics tools for Enabling Medical Decision (GOMED), led by Dr Mohammed Faruq, to see that the genome database and genetic screening leads to development of cost effective diagnostic tools and tests that are licensed out to private and public medical institutions.

The world over, fall in cost for genome sequencing (a reason for which is increase in computing power) is leading to path-breaking applications spanning the entire spectrum of healthcare - diagnosis to treatment and drug development to prevention and wellness - and unrelated fields such as agriculture, animal productivity, environment, sports and many more. Consider this: CSIR took six months to sequence the genomes of 1,008 Indians. Seventeen years ago, a global initiative led by the US National Academy of Sciences, had taken 12 years, and spent $3 billion, to complete the sequencing of the first human genome. Today, sequencing a person's genome does not cost more than $1,000. In fact, Sam Santosh, Chairman of MedGenome Labs, a private venture, says he can sequence a complete human genome in his Bengaluru lab for $500-600.

The Industry

The catalyst for the IndiGen project was advent of Next Generation Sequencing (NGS) in the last decade or so. (NGS helps an entire human genome to be sequenced in a day. The previous Sanger sequencing technology used to take over a decade.) The technology is being used by both IGIB and MedGenome for high-throughput sequencing, i.e. sequencing hundreds of thousands of genes in one go.

IndiGen is a good start but there are countries that are much ahead. Genomics England, a public-private partnership between the UK government and world's biggest NGS sequencing machine maker, Illumina, has completed sequencing of 1,00,000 genomes of British citizens comprising a mix of cancer patients, rare disorder patients and healthy people. A new agreement for sequencing of 3,00,000 genomes, with an option to increase it to 5,00,000 over the next five years, was signed by the two partners on January 13. "Countries such as Estonia and Iceland are attempting to sequence every single citizen and link the data with their health schemes. The US has decided to do it for every single rare disorder patient," says Praveen Gupta, Managing Director & Founder, Premas Life Sciences - the authorised partner of US-based Illumina in India.

"The global high-throughput genomics industry will be in the range of $10-12 billion. With an estimated 25-30 per cent annual growth, it is expected to become a $25-30 billion market in the next three-four years," he says. Premas sells tools (reagents, platforms, software, training) to labs that do genetic testing in India. With 90 per cent market share, it drives NGS technology in India, too. "The high-throughput genomics market in India, including reagents, instruments and services, will be about Rs 500 crore. Approximately 50,000 samples must be reaching India's clinical (service) market on an annual basis," says Gupta.

Dr Sridhar Sivasubbu and Dr Vinod Scaria, IGIB scientists at the forefront of the IndiGen programme, say genome sequencing is just one piece of the initiative. IGIB has two other programmes - Genomics for Understanding Rare Diseases India Alliance (GUaRDIAN) Network and Genomics and Other Omics Tools for Enabling Medical Decision (GOMED) - to ensure their genome database and genetic screening lead to development of cost-effective diagnostic tools and tests that can be licensed out to private and public healthcare institutions. "GUaRDIAN focuses on rare diseases. Given that we are a billion-plus people, even the rarest of the rare diseases is found in a few lakh people. So, this programme caters to 70 million people living with some genetic disease. We find technological solutions for these 7,000-odd diseases and partner with a network of 280 clinicians across 70-odd institutions to offer our solutions," says Sivasubbu.

"Patients and their families connect with us through the GUaRDIAN network. We sequence their genes to find the mutation, and once we find it, we go back to their communities with a cost-effective test to identify that mutation. You just have to look for that single mutation in others, and that's cost-effective," says Scaria. Instead of whole genome sequencing, which costs between Rs 50,000 and Rs 1,00,000, a single assay developed by IGIB through these programmes costs Rs 2,000. The team led by Sivasubbu and Scaria has developed 180 tests for 180 genes and transferred the technology to private diagnostic labs. The institute itself has catered to about 10,000 patients and carried about 25,000 tests in the last two years. "We have entered into partnerships with about a dozen companies. The format of the collaboration depends on the business models they follow," says Sivasubbu.

Premas Life Sciences

The authorised partner of US-based Illumina in India provides tools (reagents, platforms, software, training and troubleshooting) to labs engaged in genetic testing in India. With 90 per cent market share, it drives the New Generation Sequencing technology in India

It works in areas other than healthcare, too. For example, Tagtaste, an online platform for food professionals, uses the company's services to understand the genomics of taste. It has customers and partners such as Pepsico, Coca Cola, Nestle and ITC

Dr Lal PathLabs

The company has licensed diagnostic tests for 27 conditions from Institute of Genomics and Integrative Biology (IGIB)

Has a portfolio of more than 200 different types of tests

It is active in fields like rep- roductive health, cancer di- agnosis, pharmacogenomics

Medgenome Labs

The Bengaluru-based player considers itself as the private sector avatar of IGIB. It offers not just genetic tests but also carries out research. It has collaborated with Singapore's Nanyang Technological University to sequence 1,00,000 whole genomes from Asia. The Genome Asia project has already completed sequencing 10,000 whole genomes, of which about 8,000 are from India

MedGenomes research associates recently sequenced and analysed the genome of the Cobra snake. The findings, published in Nature, suggest the possibility of developing a new method of producing anti-venom completely in the lab.

Lifecell International

The company is in the genetic testing space. It has tied up with IGIB and offers tests ranging from basic screening (prenatal screening, newborn screening, etc) to high-end ones based on NGS. It tests more than 50,000 patient samples every month

Mahajan Imaging

The company has set up a new R&D wing to focus on cutting-edge scientific and clinical research and help radiology and genomics companies develop world-class clinically relevant products. The idea is to integrate imaging and genomic data

Trivitron Healthcare

The Chennai-based chain wants to develop tools using genomic data that can work on conventional platforms. It is talking to IGIB and trying to get its knowhow for manufacture of products for sale to pathology labs

The Private Hand

Dr Lal PathLabs, a pathology lab chain with big plans in the genetic testing space, has an entire department for such tests. "We offer tests of all levels - Karyotyping, which looks at the macro level, Microarrays, which offer intermediate resolution, and NGS, used to elucidate the DNA sequence at the micro level. The fields we are active in include prenatal reproductive health, cancer diagnosis and pharmacogenomics (study of how genes affect a person's response to drugs). We have more than 200 tests and conduct around 300 tests per day," says Dr Vandana Lal, Executive Director, Dr Lal PathLabs. The company has licensed tests for 27 conditions from IGIB. "The imported technology is expensive. The idea to partner with CSIR labs is to bring these cutting-edge technologies to Indian masses at a reasonable cost," says Dr Lal.

Lifecell International is another player in the genetic testing space that has tied up IGIB. "We offer tests ranging from basic screening (prenatal screening, newborn screening, etc.) to high-end ones based on NGS. We test more than 50,000 samples a month. PCR-based tests range from Rs 2,000-5,000 whereas tests based on NGS and those involving sequencing of large parts of the genome can cost upwards of Rs 20,000," says Ishaan Khanna, CEO, Biobank & Diagnostics, Lifecell. He believes the IndiGen database will help in development of better analysis and interpretation tools. "Our focus is on developing rapid genome testing for children in NICU (Neonatal ICU) and similar other scenarios where doctors need clear actionable results in the shortest possible time. IndiGen provides the right mix of Indian genome database," he says.

But not every partnership is for access to cost-effective tests. Mahajan Imaging, a medical imaging chain, has set up a Centre for Advanced Research in Imaging, Neuroscience and Genomics to focus on research and helping radiology and genomics companies develop clinically relevant products. The idea is to integrate imaging and genomic data. "We started the project six months ago and are among the first imaging companies to get into genomics. In the next three-five years, it will be possible for an AI algorithm to look at the radiology image and give genomic readings on it," says Vidur Mahajan, Associate Director, Mahajan Imaging.

Chennai-based Trivitron Healthcare sees in IndiGene data an opportunity to develop multiple testing platforms. It wants to develop tools using genomic data that can work on conventional platforms. "There are almost 1,00,000 pathology labs in India. Hardly 500-1,000 must be doing genetic testing. Companies like ours are talking to IGIB and trying to get the knowhow to manufacture products for a larger population," says Jameel Ahmad Khan, Head, R&D, Trivitron. "IGIB will develop the knowhow, provide proof of concept, and we will convert it into a product which pathology labs without highly trained manpower can also run," he says.

Bengaluru-based Medgenome Labs considers itself a private sector avatar of IGIB, perhaps even a couple of years ahead in research and development. The company not only does genetic tests but also carries out research. It has collaborated with Singapore's Nanyang Technological University to sequence 1,00,000 whole genomes from Asia. The Genome Asia project has already completed sequencing of 10,000 whole genomes, of which about 8,000 are from India. On December 4, international journal Nature published the initial findings from the project - genetic variation, population structure, disease associations, etc., from a whole-genome sequencing reference dataset of 1,739 individuals of 219 population groups and 64 countries across Asia. "We sequence a person's genes and other relevant parts of the genome for specific mutations to understand what is causing the disease and specific drugs and dosage the person will respond to. We also help pharmaceutical companies understand genomes and discover new drug targets and biomarkers," says Sam Santosh, Chairman, MedGenome. With about 120 sales people, the company claims it is generating samples from around 10,000 clinicians across the country. "We were the first to enter the market. In that sense, we created the market, and would be having 60-65 per cent market share. The sequencing market must be in the range of $70-75 million," says Santosh. The company expects its diagnostic business to touch $100 million in four years. Interestingly, MedGenome's research associates recently sequenced and analysed the genome of Cobra snake. The findings, published in Nature, suggest the possibility of developing a new method of producing anti-venom completely in the lab.

Other Sectors

Illumina's India partner Premas Life Sciences is not selling its next generation sequencers only to healthcare firms. Gupta says it has more than 200 installations in India alone. "Anything which is living has a DNA nucleic acid and can be sequenced. We have a mass research market and practically every institute has the sequencer. Somebody will be working on cow, somebody on rice, a third institute on some bacteria," says Gupta.

IGIB researchers Dr Sridhar Sivasubbu and Dr Vinod Scaria vouch for this. The institute is getting requests, including partnership offers, from non-medical players. Tagtaste, an online platform for food professionals, wants to understand the genomics of taste. "In a lighter vein, you could say that the efficiency of a professional wine taster depends on his genes," says Scaria. With customers and partners such as Pepsico, Coca Cola, Nestle and ITC, and a clientele that includes chefs of global hotel chains, taste is serious business. "The point is, if a person is paying Rs 3,000 for a curry or Rs 5,000 for a soup, you better get the taste right," says Scaria. IGIB also works with Adam's Genetics for R&D and product development in the area of fitness. "One of the companies works in the cricket industry. Each player can be genetically tested for performance and food intake because not all muscles have the same size and some people gain weight, some don't gain muscle mass, while some may be more prone to injury. Genetic tests can find out who is prone to injury, or whether weightlifting is the right exercise for a player or not," says Sivasubbu.

The Future

Indians are 17 per cent of the world's population. But only 0.2 per cent genomic data is from the Indian population. This is one area where India can lead. We have so many diseases, and if we can provide the genetic design, the world can develop diagnostics and therapies. "We can create ideas. We didn't invent computers but we created the IT industry. In the same way, we didn't invent genomic sequences but tomorrow we can create a genome informatics economy," says Premas' Gupta.

There are other possibilities, too. "A lot of pundits say that in the next five-six years, 15 per cent of the world's population will be whole genome sequenced. If I require 100 GB data for a genome sequence, for 1.5 billion people, 25-30 exabytes of data will be needed. The entire data content on YouTube, globally, is 0.8 exabytes. Imagine the kind of data generation and analytics possibilities we are talking about," says Gupta. "We need people to analyse this data. If we can take the lead and train our manpower, we can move the world, we can create a new industry which can lead for the next 20 years just the way the IT industry did," he adds. Incidentally, Gupta claims that TCS has already bought Illumina's sequencing platform. So has WIPRO. It seems IT companies are already sensing an opportunity.

Sivasubbu says it took India 10 years to scale up from sequencing one genome to 1,000 genomes. "In the next decade, it may be a million."

@joecmathew

Continue reading here:
The Gene Business - Business Today

Meticulous Research leading global market research company is researching on precision medicine software market titled Precision Medicine Software Market by Delivery Mode (On-Premise, Cloud-Based), Application (Oncology, Pharmacogenomics, rare diseases), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Geography-Global Forecast to 2025.

Nowadays, rising advances in big data technology applications for accurate disease detection is creating a positive impact on the precision medicine software market over the forecast period. Moreover, the introduction of various software with an improved clinical workflow will likely increase the ability to store a large amount of genetic data to ensure rapid patient recovery. The factors such as growing acceptance of big data analysis and sequencing of gene therapy are expected to drive the growth of the precision software market during the forecast period.

Download Free Sample Copy Of The Report:: https://www.meticulousresearch.com/download-sample-report/cp_id=5011

Key questions answered in the report-

What are the major drivers, restraints, challenges, and opportunities in the precision medicine software market?

Who are the major players in various countries and what share of the market do they hold?

What are the geographical trends and high growth regions/ countries?

Who are the top competitors in this market and what strategies do they employ to gain shares?

What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?

What strategies should new companies looking to enter in this market use to compete effectively?

Who are the major players in the global precision medicine software market and what share of the market do they hold?

What are the local emerging players in the global precision medicine software market and how do they compete with the global players?

Have Any Query? Ask Our Expert https://www.meticulousresearch.com/speak-to-analyst/cp_id=5011

(In case of any queries or customization requirements please connect with our Experts by Clicking Here who will ensure that your requirements are met.)

On-Premise Delivery Mode Dominated the Precision Medicine Software Market in 2018

On the basis of delivery mode, the precision medicine software market is segmented into on-premise and cloud-based delivery model. On-premises commanded the largest share of precision medicine software market in 2018. The large market share of this segment is primarily attributed to the wide range of advantages regarding the use of on-premise delivery model. However, cloud-based delivery mode segment is expected to grow at the highest rate during the forecast period due to its rising adoption in healthcare organizations for sharing and integrating information from different locations.

Health Providers to Register the Highest Growth, by End User

On the basis of end user, the precision farming software market is segmented into healthcare providers, research centers & government institutes, pharmaceutical & biotechnology companies, and others. Health provider commanded the largest share of the precision software market in 2018 with the growing availability of precision medicine software and a rising emphasis on providing personalized medicine in hospitals.

You Can Directly Buy This Report From Here:: https://www.meticulousresearch.com/buy_now.php?pformat=310&vformat=921

(Get key industry insights spread across 280 pages with 256 market data tables & 61 figures & charts from the report)

North America Dominates the Market, While Asia Pacific Leads the Growth

North America commanded the largest share of the precision medicine software market in 2018, followed by Europe and Asia Pacific. The major share of this region is mainly attributed to the increase in the geriatric population suffering from chronic diseases such as cancer. In addition, rising government investment and favorable initiatives for the implementation of precision medicine software further support the growth of the North American precision medicine software market. However, Asia-Pacific region is projected to grow at a significant pace in the next few years, mainly due to the growing burden of genetic diseases throughout the region.

Key Players in the Precision Medicine Software Market

The key players operating in the globalprecision medicine software marketareSyapse, Inc. (U.S.), Fabric Genomics, Inc (U.S.), SOPHiA GENETICS SA (France), Human Longevity, Inc. (U.S.), Sunquest Information Systems, Inc. (U.S.), Lifeomic Health, LLC (U.S.), 2bPrecise LLC (U.S.), Foundation Medicine Inc. (U.S.), PierianDx Inc. (U.S.), Gene42 Inc. (Canada), N-of-One Inc. (A Subsidiary of Qiagen N.V.) (U.S.), and Translational Software Inc. (U.S.).

Download Free Sample Copy Of The Report:: https://www.meticulousresearch.com/download-sample-report/cp_id=5011

Related Reports::

1Healthcare Barcode Technology Market Size by Product (Barcode Printers, Barcode Verifiers, and Barcode Scanners) by application (Clinical and Non-Clinical) Global Forecasts to 2022

2 Artificial Intelligence In Healthcare Market By Product (Hardware, Software, Services), Technology (Machine Learning, Context-Aware Computing, NLP), Application (Drug Discovery, Precision Medicine), End User, And Geography Global Forecast To 2025

3 Clinical Trial Materials and Supplies Market by Service (Logistics, Manufacturing), Clinical Trial Type (Therapeutic, Diagnostics), Phase (Phase 2, Phase 3), Medical Specialty (Oncology, Diabetes), and End User (Pharmaceutical, CRO)- Global Forecast to 2025

About Meticulous Research

The name of our company defines our services, strengths, and values. Since its inception, we have only thrived to research, analyze and present the critical market data with great attention to details. Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

Contact Us:

Meticulous ResearchEmail-sales@meticulousresearch.comContact Sales- +1-646-781-8004Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Originally posted here:
Precision Medicine Software Market to Register the Highest Growth Rate by Applications, and Future F - PharmiWeb.com

Latest Market Research Report onProtein Detection and Quantitation Market size | Industry Segment by Applications (Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology and Breeding and Animal Livestock), by Type (Bradford, Coomassie and BCA), Regional Outlook, Market Demand, Latest Trends, Protein Detection and Quantitation Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report on Protein Detection and Quantitation market strive to provide business professionals with an updated information on Protein Detection and Quantitation market, high growth markets, emerging business environments and latest business-centric applications. The Protein Detection and Quantitation market Analysis report provides a detailed analysis of sales channel and regional analysis of the Protein Detection and Quantitation market.

Likewise, Protein Detection and Quantitation Market report also assesses the key opportunities in the Protein Detection and Quantitation market and outlines the factors that are and will be driving the growth of the Protein Detection and Quantitation market share in current industry. The Protein Detection and Quantitation report is analyzed and forecasted for the previous and next five years of industry.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/85491

The key Protein Detection and Quantitation market players are weighed on a variety of factors such as company overview, product portfolios and recent development of the global Protein Detection and Quantitation market.

Top key playersof industry are covered in Protein Detection and Quantitation Market Research Report:

Split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into:

Split by application,this report focuses on consumption, market share and growth rate of Protein Detection and Quantitation market in each application and can be divided into:

The predictions highlighted in the Protein Detection and Quantitation market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Protein Detection and Quantitation market. Across the past few years, the Protein Detection and Quantitation have seen the rise of influential market leaders in the space. The competition in the global Protein Detection and Quantitation market is dominated by the big players: Thermo Fisher Scientific, Promega, Genecopoeia, Labome and Garland Science

The Protein Detection and Quantitation market has shown growing trends over the years and anticipations are made that the Protein Detection and Quantitation market size would grow at a speedy pace in the upcoming years. Growth in the Protein Detection and Quantitation market would be primarily driven by application areas such as Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology and Breeding and Animal Livestock and product types segment like Bradford, Coomassie and BCA.

Outline of Protein Detection and Quantitation Market report covers:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/85491

See the rest here:
Protein Detection and Quantitation Market Forecast 2020-2025, Latest Trends and - News by aeresearch

Coherent Market Insights proclaims the obtainability of a new statistical data to its repository titled as, Pharmacogenomics market 2020 2027. It covers the wide-ranging aspects of the businesses such as pillars, features, sales strategies, planning models to get better insights for the businesses. Furthermore, it throws light on recent developments and technological platforms, several tools, and methodologies that help to boost the performance of industries.

This Pharmacogenomics Market report profiles major topmost manufactures operating Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc. in terms of analyse various attributes such as Production, Consumption, Revenue, Gross Margin, Cost, Gross, Market Share, CAGR, and Market Influencing Factors of the Pharmacogenomics industry in USA, EU, China, India, Japan and other regions.

Download PDF with Recent all Updates & Trending Key Players with TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1053

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Pharmacogenomics Market Taxonomy

The Pharmacogenomics Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts and industry participants across the value chain. The research report market provides an in depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Geographically, this report is segmented into several key regions,with sales, revenue, market share and growth Rate of Pharmacogenomics in these regions, from 2019 to 2027, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Different sales strategies have been elaborated to get a clear idea for getting global clients rapidly. It helps various industry experts, policymakers, business owners as well as various c level people to make informed decisions in the businesses. It includes the massive data relating to the technological advancements, trending products or services observed in the market. The major key pillars of businesses such as global Pharmacogenomics market are explained in a concise manner and effectively for fueling the progress of the market.

Our Study Report Offers:

Market share analysis for the regional and country level segments.

Pharmacogenomics Market share analysis of the best business players.

Strategic proposal for the new entrants.

Market forecasts for next five years of all the mentioned segments, sub segments and conjointly the regional markets.

Market Opportunities, Trends, Constraints, Threats, Challenges, Drivers, Investment and suggestions.

Strategic steerage in key business segments supported the market estimations.

Competitive landscaping mapping the key common trends.

Company identification with careful methods, financials, and up so far developments.

provide chain trends mapping the foremost recent technological advancements.

The reports conclusion reveals the overall scope of the Global Pharmacogenomics Market in terms of feasibility of investments in the various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the market in the near future.

Queries regarding the report can be addressed to Coherent Market Insights analysts @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1053

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

See the rest here:
Pharmacogenomics Market In-depth Study on Analysis and Forecast 2020-2027 - Redhill Local Councillors

The "Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies" report has been added to ResearchAndMarkets.com's offering.

Increasing prevalence of Infectious diseases such as Influenza, HPV, Hepatitis, HIV and Tuberculosis despite rise in sanitation practices globally. In the past, antimicrobials medicines were used to fight powerful infectious disease but slowly in today's time antimicrobial agent is not able to give the desired results because the problem of drug resistant occurs in many people across the world.

Nowadays, a new diagnostic procedure is being followed to fight infectious disease like molecular diagnostic test is very effective which is quite fast and precise. The number of cancer patients is increasing very fast, so it is believed that in the coming time the molecular diagnostic test market will be growing at rapid pace. Global Molecular Diagnostics Market is likely to surpass US$ 22.5 Billion by the end of year 2025.

There are various reasons that will propel the market growth in forecast year; rising incidence rate of infectious disease, increasing incidence rate of cancer of all type, increasing people awareness regarding molecular diagnostic, rapid technological growth, widely acceptance of personalized medicine, rising healthcare infrastructure, increasing healthcare per capita expenditure across the developed and developing nation, accuracy of diagnosis, growing population of cardiovascular and neurological disorder etc. In addition, increasing prevalence of genetic disorder will further boost the market in forecast period of time.

The report titled Molecular Diagnostics Market Share & Forecast, By Application (Infectious Diseases, Blood Screening, Oncology, Genetic Testing, HLA (Tissue Typing), Microbiology, Cardiovascular Diseases, Neurological Diseases, Pharmacogenomics and Others), By Technology (PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others), By End User (Hospitals & Academic Laboratories, Clinics and Commercial Laboratories, Others), By Regions [United States, Europe (Expect Russia), India, China, Japan, Brazil, South Korea, Mexico, Russia and ROW], Companies (Roche, Abbott, Myriad Genetics, Qiagen, BioMrieux and Others) provides a complete analysis of Molecular Diagnostics Market.

Story continues

Market Insight by Application

The report provides comprehensive analysis of molecular diagnostic test market by application into ten parts: Infectious Diseases, Genetic Testing, Blood Screening, Oncology, HLA (Tissue Typing), Microbiology, Neurological Diseases, Pharmacogenomics, Cardiovascular Diseases, and Others. This report also provides key opportunities market and specific factors are given by each application market.

Market Insight by Technology

Here the market is fragmented into six parts; PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others. Besides, many factors are analyzed that influence the growth, challenges and opportunities of market in technological context.

Market Insight by End User

The report provides complete insight of market by End User segments: Hospitals & Academic Laboratories, Clinics & Commercial Laboratories and Others. According to the publisher, Hospitals & Academic Laboratories will hold the largest market in global molecular diagnostic test market in forecast period of time.

Market Insight by Regions

This report covers the complete regional profile by 10 geographical market; United States, Europe, India, China, Japan, Brazil, South Korea, Mexico, Russia and Rest of World (ROW).

Key Topics Covered:

1. Executive Summary

2. Global Molecular Diagnostic Market

3. Market Share - Global Molecular Diagnostics

3.1 By Application

3.2 By Technology

3.3 By Countries

3.4 By Companies

4. Application - Molecular Diagnostics Market

4.1 Infectious Diseases

4.1.1 Hospital Acquired Infections (HAI)

4.1.2 HIV / HCV Testing

4.1.3 STD Testing

4.1.4 HPV Testing

4.2 Blood Screening

4.3 Oncology / Cancer

4.3.1 Breast

4.3.2 Colorectal

4.3.3 Prostate

4.3.4 Others

4.4 Genetic Testing

4.5 HLA (Tissue Typing)

4.6 Microbiology

4.7 Cardiovascular Diseases

4.8 Neurological Diseases

4.9 Pharmacogenomics

4.10 Others

5. Technology - Molecular Diagnostics Market

5.1 PCR

5.2 Transcription-Mediated Amplification (TMA)

5.3 Hybridiazation (In-situ Hybridiazation & FISH)

5.4 DNA Sequencing & NGS

5.5 Microarray

5.6 Others

6. Region - Molecular Diagnostics Market

6.1 United States

6.2 Europe

6.3 India

6.4 China

6.5 Japan

6.6 Brazil

6.7 South Korea

6.8 Mexico

6.9 Russia

6.10 Rest of World (ROW)

7. End Users - Molecular Diagnostics Market

7.1 Hospitals & Academic Laboratories

7.2 Clinics and Commercial Laboratories

7.3 Others

8. Roche Diagnostics - Company Analysis

8.1 Merger & Acquisitions

8.2 Sales Analysis

9. Abbott Laboratories - Company Analysis

9.1 Merger & Acquisitions

9.2 Sales Analysis

10. Myriad Genetics - Company Analysis

10.1 Merger & Acquisitions

10.2 Sales Analysis

11. Qiagen - Company Analysis

11.1 Merger & Acquisitions

11.2 Sales Analysis

12. BioMrieux's Inc - Company Analysis

12.1 Merger & Acquisitions

12.2 Sales Analysis

13. Market Drivers

13.1 Various Developments in the Molecular Diagnostics Landscape

13.2 Integral to Traditional Labs

13.3 Improved Assay / Test Efficiencies

13.4 Targeting Antibiotic Resistance

13.5 Next Generation Ultrasensitive Molecular Diagnostics

13.6 Increasing Investment in Genomics & Proteomics Research

13.7 Technological Advances in Molecular Diagnostics

13.8 Increasing Acceptance of the Personalized Medicine

13.9 Growing Molecular Diagnostics for Food Safety

14. Challenges

14.1 Dearth of Trained Professionals

14.2 Regulatory Issues

14.3 Various Factors Slowing Growth of Molecular Diagnostics

14.4 Reimbursement Capabilities

14.5 Quality Checkpoints, Awareness & Acceptance

For more information about this report visit https://www.researchandmarkets.com/r/j3on5s

View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005474/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Global Molecular Diagnostics Market is Likely to Surpass US$ 22.5 Billion by the End of Year 2025 - ResearchAndMarkets.com - Yahoo Finance